Rigel Pharmaceuticals announced that REZLIDHIA has been added by the National Comprehensive Cancer Network to the latest NCCN Clinical Practice Guidelines in Oncology for acute myeloid leukemia. REZLIDHIA is now included as a recommended targeted therapy for adult patients with relapsed/refractory AML with isocitrate dehydrogenase-1 mutation.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RIGL:
- Rigel Pharmaceuticals sees Q4 revenue $51.3M, consensus $21.65M
- Analysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
- Rigel Pharmaceuticals says REZLIDHIA now available in U.S. by prescription
- Rigel Pharmaceuticals doses first patient in Phase 1b study of R289
- Optime Care announces enhanced partnership with Rigel Pharmaceuticals